Comparative Pharmacology
Head-to-head clinical analysis: DIPRIVAN versus ETOMIDATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPRIVAN versus ETOMIDATE.
DIPRIVAN vs ETOMIDATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propofol potentiates GABA-A receptor activity, leading to rapid sedation and hypnosis by enhancing chloride conductance and neuronal hyperpolarization.
Etomidate is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) type A receptor, enhancing GABA-mediated inhibition in the central nervous system. It produces rapid anesthesia with minimal cardiovascular and respiratory depression.
Induction: 2-2.5 mg/kg IV bolus; maintenance: 25-75 mcg/kg/min IV infusion.
Induction: 0.2–0.6 mg/kg IV over 30–60 seconds. Maintenance: 10–20 mcg/kg/min IV continuous infusion.
None Documented
None Documented
Clinical Note
moderateEtomidate + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Etomidate is combined with Fluticasone propionate."
Clinical Note
moderateEtomidate + Clemastine
"The risk or severity of adverse effects can be increased when Etomidate is combined with Clemastine."
Clinical Note
moderateEtomidate + Venlafaxine
"Etomidate may decrease the antihypertensive activities of Venlafaxine."
Clinical Note
moderateEtomidate + Nefazodone
Terminal elimination half-life: 4-7 hours (with context of context-sensitive half-life increasing after prolonged infusion).
Terminal elimination half-life: 2.9–5.3 hours (context: redistribution shortens clinical effect; hepatic impairment prolongs).
Renal (approximately 88% as metabolites, <1% unchanged); fecal (approximately 2%); other (10% as metabolites via other routes).
Renal: 75% as metabolite (carboxylic acid), 2% unchanged; fecal/biliary: minimal.
Category C
Category C
General Anesthetic
General Anesthetic
"The risk or severity of adverse effects can be increased when Etomidate is combined with Nefazodone."